[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"hepatic-failure\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:hepatic-failure":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,45],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":31,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":40,"leadSponsor":42,"locationsCount":4},"100640735","personalized-two-stage-regional-citrate-anticoagulation-for-crrt-in-patients-with-citrate-metabolism-impairment-100640735",false,"NCT07579663","Personalized Two-stage Regional Citrate Anticoagulation for CRRT in Patients With Citrate Metabolism Impairment","Personalized Two-stage Regional Citrate Anticoagulation for CRRT in Patients With Citrate Metabolism Impairment: a Multicenter Randomized Controlled Study","PRECISE","Inclusion Criteria:\n\nA. Aged 18 to 80 years, inclusive, male or female; B. Diagnosed with acute kidney injury or chronic kidney disease stage 5, and assessed by a physician as requiring continuous renal replacement therapy (CRRT); C. Citrate metabolism disorder, including liver failure (acute liver failure, acute-on-chronic liver failure, or decompensated cirrhosis), and\u002For microcirculation disorder (mean arterial pressure \\\u003C65 mmHg requiring vasopressor therapy and lactate ≥2 mmol\u002FL); D. The investigator determines that the patient can have a stable vascular access established (the access must be capable of providing a constant and effective blood flow rate \\>150 ml\u002Fmin); E. The study participant (subject) and their legal guardian are able to understand the study purpose and provide written informed consent.\n\nExclusion Criteria:\n\nA. Received regional citrate anticoagulation therapy within the previous 72 hours; B. Expected to require additional non-protocol calcium supplementation during CRRT due to disease-related needs; C. Requiring arterial-venous reversal of the extracorporeal circuit during CRRT due to poor flow; D. Requiring concurrent peritoneal dialysis during the trial period; E. Participated in or is currently participating in another clinical trial within 1 month prior to the date of signing the informed consent form; F. Expected survival time less than 72 hours; G. Any other conditions that, in the investigator's judgment, make the patient unsuitable for participation in the clinical trial.","ALL","18 Years","80 Years",{"count":21,"type":22},142,"ESTIMATED","INTERVENTIONAL",[25],"NA","The purpose of this study is to compare the efficacy and safety of an individualized two-stage calcium supplementation method versus a conventional commercial RCA-CRRT module in RCA-CRRT for patients with citrate metabolism disorders.",[28,29,30],"AKI - Acute Kidney Injury","CKD 5D, Hemodialysis","Hepatic Failure",[32,33],"Regional Citrate Anticoagulation (RCA)","Continuous Renal Replacement Therapy (CRRT)","NOT_YET_RECRUITING","2026-05-05",{"date":37,"type":38},"2026-05-12","ACTUAL",{"date":35,"type":22},{"date":41,"type":22},"2028-08-14",{"name":43,"class":44},"Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University","OTHER",{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":23,"phases":54,"briefSummary":55,"conditions":56,"keywords":59,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":69,"leadSponsor":71,"locationsCount":73},"100593280","perioperative-use-of-amino-acids-in-recipients-of-orthotopic-liver-transplantation-as-a-renal-protective-factor-100593280","NCT07004387","Perioperative Use of Amino Acids in Recipients of Orthotopic Liver Transplantation as a Renal Protective Factor","PAATHO","Inclusion Criteria:\n\n* All patients assigned to receive a liver transplant will be evaluated for eligibility.\n* Patients over 18 years old scheduled for a liver transplant will be considered eligible if it is expected that they will have an ICU stay of at least 24 hours in the immediate postoperative period, regardless of the cause of liver failure and whether it was stable liver failure or acute on chronic liver failure.\n* They must have a baseline measurement of serum creatinine that does not exceed 30 days prior to surgery or can be taken before the transplant surgery.\n\nExclusion Criteria:\n\n* Patients under 18 years old will be excluded.\n* Patients with a need for chronic hemodialysis, patients with chronic kidney disease with an estimated glomerular filtration rate of less than 30 ml per minute per 1.73 square meters of body surface area calculated by the Cockcroft-Gault equation.\n* Patients with acute renal failure requiring acute intermittent or continuous renal replacement therapy during the hospitalization for surgery.\n* Patients who refuse informed consent to participate in the study.",{"count":53,"type":22},90,[25],"Orthotopic liver transplantation is the definitive treatment for end-stage liver failure, with renal failure being an important complication of this procedure that has implications for long- and short-term prognosis, affecting ICU stay and hospitalization time. Several studies have suggested that intravenous amino acids, particularly L-arginine, may have protective effects on renal function due to increased renal blood flow, which could be explained by enhanced production of nitric oxide among other mechanisms that are still unclear. In this context, we developed the hypothesis that the infusion of an amino acid solution in the perioperative period could reduce the incidence of acute renal failure in this group of patients; for this, we conducted a monocentric, analytical, prospective, interventional pilot study comparing standard treatment (in historically transplanted patients) with a group of patients who were administered amino acids in the perioperative period, considering that this medication is low-cost and has practically minimal side effects.",[30,57,58],"Liver Transplant","Renal Failure, Acute",[60,61,62,63,64],"liver transplant","renal failiure","amino acids","surguery","ICU","2025-05-27",{"date":67,"type":38},"2025-06-04",{"date":65,"type":22},{"date":70,"type":22},"2026-09-30",{"name":72,"class":44},"Hospital Dr Sotero del Rio",1]